ClinicalTrials.gg
CompletedNCT04465877Updated Jan 27, 2023Results posted

Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes

A Phase 1 interventional study of JTT-662 and Placebo in Diabetes Mellitus, Type 2, sponsored by Akros Pharma Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-01-27.

Sponsored by Akros Pharma Inc. (part of Shionogi) · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States — 345 open to participants now, 479 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.

Enrollment
2,116th of 2,961
37 · median 90
Started
2020
with 96 others
Phase 1
384 of 3,308
25 open now
Registered
2,369th of 3,308
by date

Among the 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 2,116th largest by enrollment of the 2,961 interventional ones that give a count, is one of 97 that started in 2020, is one of 384 in phase 1, and was the 2,369th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

345 of the 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:

340 more — sign in →

All 345 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of JTT-662 administered once daily for 28 days in subjects with Type 2 diabetes mellitus (T2DM) who are receiving metformin monotherapy

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • JTT-662
  • Diabetes
  • Safety
  • Tolerability
  • Pharmacokinetics
  • Pharmacodynamics
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of T2DM for at least 12 weeks prior to the Screening Visit
  • Currently treated with a stable oral dose of metformin monotherapy for at least 12 weeks prior to the Screening Visit and until Day -3
  • Have a glycosylated () value of between 6.5% and 10.0% at the Screening Visit
  • Have a fasting plasma glucose (FPG) value of no more than 280 mg/dL at the Screening Visit and on Day -3
  • (BMI) of 25 to 40 kg/m2 (inclusive)

Exclusion criteria

Exclusion Criteria:

  • Known medical history or presence of Type 1 diabetes mellitus, Maturity Onset Diabetes of the Young or secondary forms of diabetes
  • Known medical history or presence of diabetic complications
  • Have taken anti-diabetic medications (other than metformin) or medications that act mainly in the gastrointestinal tract (e.g., orlistat, acarbose) within 12 weeks prior to the Screening Visit or from the Screening Visit to Day -3
  • Have uncontrolled hypertension (systolic blood pressure of at least 160 mmHg or diastolic blood pressure of at least 95 mmHg) at the Screening Visit
  • Have impaired renal function (estimated (eGFR) \<60 mL/min/1.73 m2)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    JTT-662 5 mg

    JTT-662 5 mg orally once daily from Day 1 to Day 28, after a single dose of placebo on Day -1

    Drug: JTT-662

  • Experimental
    JTT-662 10 mg

    JTT-662 10 mg orally once daily from Day 1 to Day 28, after a single dose of placebo on Day -1

    Drug: JTT-662

  • Experimental
    JTT-662 20 mg

    JTT-662 20 mg orally once daily from Day 1 to Day 28, after a single dose of placebo on Day -1

    Drug: JTT-662

  • Placebo comparator
    Placebo

    Placebo orally once daily from Day -1 to Day 28

    Drug: Placebo

Interventions

  • DrugJTT-662

    Active drug tablets containing JTT-662

  • DrugPlacebo

    Placebo tablets matching in appearance to the active drug tablets

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Treatment-emergent Adverse Events

    Treatment-emergent adverse event is defined as any adverse event (untoward medical experience occurring to a subject whether or not it is related to the study drug) with an onset date/time at/after the placebo dosing on Day -1.

    Time frame: 6 Weeks (from Day -1 to the follow-up visit on Day 42)

  2. Number of Stools and Type of Stools Based on Bristol Stool Chart

    Number of occurrences for each stool type was reported based on their type assessed from Bristol Stool Chart. The Bristol Stool Chart was used to assess the stool shape using a 7-point scale. Where, Type 1 = separate hard lumps, like nuts (hard to pass), Type 2 = sausage-shaped but lumpy, Type 3 = like a sausage but with cracks on the surface, Type 4 = like a sausage or snake, smooth and soft, Type 5 = soft blobs with clear-cut edges (passed easily), Type 6 = fluffy pieces with ragged edges, a mushy stool, Type 7 = watery, no solid pieces; entirely liquid. A score of 1 or 2 indicates constipation while a score of 6 or 7 indicates diarrhea.

    Time frame: 7 Weeks (from Day -6 to the follow-up visit on Day 42)

  3. Trough Concentrations of JTT-662 in Plasma on Days 1, 7, 10, 14, 15, 21 and 28

    Trough plasma concentration is the measured concentration at the end of a dosing interval at steady state (taken directly before next administration). Blood samples were collected at specific timepoints to measure trough plasma concentrations of JTT-662 in the subjects randomized to JTT-662 treatment groups.

    Time frame: 28 Days

  4. Change From Baseline in AUEC0-4 for Plasma Postprandial Glucose (PPG) Compared to Placebo on Days 1, 14 and 28

    Change from baseline in the AUEC0-4 (area under the observed effect-time curve from the start of breakfast until the 4 hour time point) for PPG were calculated using the corresponding Day -1 value as baseline and compared to the placebo values. Negative values represent greater reduction in PPG from baseline values compared to placebo.

    Time frame: Days 1, 14 and 28

07

Results

Posted Jan 27, 2023

Participant flow

Written informed consent was obtained prior to performing any study-related procedures. A copy of the informed consent was provided to each subject enrolled in this study. To qualify for the study, subjects were required to satisfy defined criteria.

Participant flow — Overall Study
MilestoneJTT-662 5 mgJTT-662 10 mgJTT-662 20 mgPlacebo
Started99109
Randomized population99109
Safety population99109
Pk (pharmacokinetic) population99100
Pd (pharmacodynamic) population99109
Completed9999
Not completed0010
Withdrew: Noncompliant with study requirements0010

Outcome measures

PrimaryNumber of Subjects With Treatment-emergent Adverse Events

Treatment-emergent adverse event is defined as any adverse event (untoward medical experience occurring to a subject whether or not it is related to the study drug) with an onset date/time at/after the placebo dosing on Day -1.

Time frame:
6 Weeks (from Day -1 to the follow-up visit on Day 42)
Reported as:
Count of participants · Participants
Number of Subjects With Treatment-emergent Adverse Events
ParticipantsJTT-662 5 mgJTT-662 10 mgJTT-662 20 mgPlaceboPlacebo Run-in
Number of subjects with TEAEs471063
Number of subjects with no TEAEs520334
PrimaryNumber of Stools and Type of Stools Based on Bristol Stool Chart

Number of occurrences for each stool type was reported based on their type assessed from Bristol Stool Chart. The Bristol Stool Chart was used to assess the stool shape using a 7-point scale. Where, Type 1 = separate hard lumps, like nuts (hard to pass), Type 2 = sausage-shaped but lumpy, Type 3 = like a sausage but with cracks on the surface, Type 4 = like a sausage or snake, smooth and soft, Type 5 = soft blobs with clear-cut edges (passed easily), Type 6 = fluffy pieces with ragged edges, a mushy stool, Type 7 = watery, no solid pieces; entirely liquid. A score of 1 or 2 indicates constipation while a score of 6 or 7 indicates diarrhea.

Time frame:
7 Weeks (from Day -6 to the follow-up visit on Day 42)
Reported as:
Number · Number of stools
Number of Stools and Type of Stools Based on Bristol Stool Chart
Number of stoolsJTT-662 5 mgJTT-662 10 mgJTT-662 20 mgPlacebo
Total Number of Stools491550815599
Type 115394
Type 231121117
Type 3412118102
Type 4226173119329
Type 56311710697
Type 6739424225
Type 74213031025
PrimaryTrough Concentrations of JTT-662 in Plasma on Days 1, 7, 10, 14, 15, 21 and 28

Trough plasma concentration is the measured concentration at the end of a dosing interval at steady state (taken directly before next administration). Blood samples were collected at specific timepoints to measure trough plasma concentrations of JTT-662 in the subjects randomized to JTT-662 treatment groups.

Time frame:
28 Days
Reported as:
Mean · ng/mL
Trough Concentrations of JTT-662 in Plasma on Days 1, 7, 10, 14, 15, 21 and 28
ng/mLJTT-662 5 mgJTT-662 10 mgJTT-662 20 mg
Day 160.2 ± 14.4124 ± 36.0231 ± 61.9
Day 7209 ± 61.5518 ± 155845 ± 359
Day 10235 ± 64.3629 ± 181959 ± 449
Day 14257 ± 97.3703 ± 2241130 ± 502
Day 15266 ± 83.7689 ± 2091140 ± 475
Day 21281 ± 100787 ± 2371180 ± 665
Day 28292 ± 103786 ± 3261190 ± 583
PrimaryChange From Baseline in AUEC0-4 for Plasma Postprandial Glucose (PPG) Compared to Placebo on Days 1, 14 and 28

Change from baseline in the AUEC0-4 (area under the observed effect-time curve from the start of breakfast until the 4 hour time point) for PPG were calculated using the corresponding Day -1 value as baseline and compared to the placebo values. Negative values represent greater reduction in PPG from baseline values compared to placebo.

Time frame:
Days 1, 14 and 28
Reported as:
Least squares mean · mg*hr/dL
Change From Baseline in AUEC0-4 for Plasma Postprandial Glucose (PPG) Compared to Placebo on Days 1, 14 and 28
mg*hr/dLJTT-662 5 mgJTT-662 10 mgJTT-662 20 mgPlacebo
Day 1-0.34 (-55.64 to 54.96)-98.24 (-153.78 to -42.69)-88.19 (-140.71 to -35.67)1.78 (-54.00 to 57.57)
Day 14-31.22 (-106.31 to 43.88)-169.40 (-244.67 to -94.13)-253.57 (-324.85 to -182.29)-31.55 (-106.99 to 43.89)
Day 28-61.17 (-154.63 to 32.28)-230.87 (-324.46 to -137.28)-250.64 (-340.71 to -160.58)-1.83 (-95.55 to 91.90)
Statistical analysis
  • JTT-662 5 mg vs Placebo · Mixed Models Analysis · p = 0.956 · Mean difference (final values): -2.12 · 95% CI -79.67 to 75.42
  • JTT-662 5 mg vs Placebo · Mixed Models Analysis · p = 0.995 · Mean difference (final values): 0.33 · 95% CI -105.41 to 106.07
  • JTT-662 5 mg vs Placebo · Mixed Models Analysis · p = 0.366 · Mean difference (final values): -59.35 · 95% CI -191.15 to 72.45
  • JTT-662 10 mg vs Placebo · Mixed Models Analysis · p = 0.016 · Mean difference (final values): -100.02 · 95% CI -179.96 to -20.08
  • JTT-662 10 mg vs Placebo · Mixed Models Analysis · p = 0.014 · Mean difference (final values): -137.85 · 95% CI -245.28 to -30.43
  • JTT-662 10 mg vs Placebo · Mixed Models Analysis · p = 0.001 · Mean difference (final values): -229.04 · 95% CI -362.17 to -95.91
  • JTT-662 20 mg vs Placebo · Mixed Models Analysis · p = 0.025 · Mean difference (final values): -89.98 · 95% CI -167.62 to -12.33
  • JTT-662 20 mg vs Placebo · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -222.02 · 95% CI -326.54 to -117.51
  • JTT-662 20 mg vs Placebo · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -248.82 · 95% CI -379.35 to -118.28

Adverse events

Collected over Up to 6 weeks (from Day -1 to the follow-up visit on Day 42). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
JTT-662 5 mg0/9 (0%)0/9 (0%)4/9 (44.4%)
JTT-662 10 mg0/9 (0%)0/9 (0%)7/9 (77.8%)
JTT-662 20 mg0/10 (0%)0/10 (0%)10/10 (100%)
Placebo0/9 (0%)0/9 (0%)6/9 (66.7%)
Placebo Run-in0/37 (0%)0/37 (0%)3/37 (8.1%)
Most frequent other events
Showing 10 of 20
Most frequent other events
EventJTT-662 5 mgJTT-662 10 mgJTT-662 20 mgPlaceboPlacebo Run-in
DiarrhoeaGastrointestinal disorders3/95/910/101/92/37
Anorectal discomfortGastrointestinal disorders0/91/93/100/90/37
DyspepsiaGastrointestinal disorders0/90/92/100/90/37
NauseaGastrointestinal disorders1/90/92/100/90/37
Abdominal distensionGastrointestinal disorders1/91/91/100/90/37
AbscessInfections and infestations0/90/90/101/90/37
HordeolumInfections and infestations0/90/90/101/90/37
Skin infectionInfections and infestations0/90/90/101/90/37
Urinary tract infectionInfections and infestations0/91/90/100/90/37
Limb injuryInjury, poisoning and procedural complications0/90/90/101/90/37

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)JTT-662 5 mgJTT-662 10 mgJTT-662 20 mgPlaceboTotal
<=18 years00000
Between 18 and 65 years8810935
>=65 years11002
Sex: Female, Male
Sex: Female, Male(Participants)JTT-662 5 mgJTT-662 10 mgJTT-662 20 mgPlaceboTotal
Female464216
Male536721
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)JTT-662 5 mgJTT-662 10 mgJTT-662 20 mgPlaceboTotal
Hispanic or Latino9910937
Not Hispanic or Latino00000
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)JTT-662 5 mgJTT-662 10 mgJTT-662 20 mgPlaceboTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American00213
White998834
More than one race00000
Unknown or Not Reported00000
08

Study locations

1 site
  • Qps-Mra, Llc
    Miami, Florida 33143, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Feb 2021, 8 months.

Results were first posted in Jan 2023, 1 year 11 months after primary completion.

Of 454 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 8 months is above that.

Counting every sponsor, half of 517 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2020
First posted
Jul 10, 2020
StartActual
Jun 15, 2020
Primary completionActual
Feb 17, 2021
CompletionActual
Feb 17, 2021
Results first posted
Jan 27, 2023
Last update
Jan 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04465877
Lead sponsor
Akros Pharma Inc.
Responsible party
Sponsor
First posted
Jul 10, 2020
Start date
Jun 15, 2020
Primary completion
Feb 17, 2021
Completion
Feb 17, 2021
Results posted
Jan 27, 2023
Last update
Jan 27, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion